Literature DB >> 20005786

Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone.

Louis Le Heron1, Christine Guillaume, Frédéric Velard, Julien Braux, Lhousseine Touqui, Sandra Moriceau, Isabelle Sermet-Gaudelus, Dominique Laurent-Maquin, Jacky Jacquot.   

Abstract

Bone loss is an important clinical issue in patients with cystic fibrosis (CF). Whether the cystic fibrosis transmembrane conductance regulator (CFTR) plays a direct role in bone cell function is yet unknown. In this study, we provide evidence that inhibition of CFTR-Cl(-) channel function results in a significant decrease of osteoprotegerin (OPG) secretion accompanied with a concomitant increase of prostaglandin (PG) E(2) secretion of primary human osteoblast cultures (n=5). Our data therefore suggest that in bone cells of CF patients, the loss of CFTR activity may result in an increased inflammation-driven bone resorption (through both the reduced OPG and increased PGE(2) production), and thus might contribute to the early bone loss reported in young children with CF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005786     DOI: 10.1016/j.jcf.2009.11.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  16 in total

Review 1.  Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.

Authors:  J Jacquot; M Delion; S Gangloff; J Braux; F Velard
Journal:  Osteoporos Int       Date:  2015-10-02       Impact factor: 4.507

2.  Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis.

Authors:  Melissa S Putman; Carly E Milliren; Nicholas Derrico; Ahmet Uluer; Leonard Sicilian; Allen Lapey; Gregory Sawicki; Catherine M Gordon; Mary L Bouxsein; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2014-06-13       Impact factor: 5.958

3.  Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period.

Authors:  Melissa S Putman; Joshua F Baker; Ahmet Uluer; Karen Herlyn; Allen Lapey; Leonard Sicilian; Angela Pizzo Tillotson; Catherine M Gordon; Peter A Merkel; Joel S Finkelstein
Journal:  J Cyst Fibros       Date:  2015-02-16       Impact factor: 5.482

4.  Children and adolescents with cystic fibrosis display moderate bone microarchitecture abnormalities: data from high-resolution peripheral quantitative computed tomography.

Authors:  C Braun; J Bacchetta; P Braillon; R Chapurlat; J Drai; P Reix
Journal:  Osteoporos Int       Date:  2017-08-09       Impact factor: 4.507

5.  Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis.

Authors:  M S Putman; L B Greenblatt; L Sicilian; A Uluer; A Lapey; G Sawicki; C M Gordon; M L Bouxsein; J S Finkelstein
Journal:  Osteoporos Int       Date:  2016-03-07       Impact factor: 4.507

Review 6.  Endocrine Disorders in Cystic Fibrosis.

Authors:  Scott M Blackman; Vin Tangpricha
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

Review 7.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

Review 8.  Bisphosphonates for osteoporosis in people with cystic fibrosis.

Authors:  Louise S Conwell; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2014-03-14

Review 9.  [Cystic fibrosis being a polyendocrine disease (Review)].

Authors:  N B Chagay; G Ya Khayt; T M Vdovina; A A Shaforost
Journal:  Probl Endokrinol (Mosk)       Date:  2021-03-30

10.  The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis.

Authors:  Melissa S Putman; Logan B Greenblatt; Michael Bruce; Taisha Joseph; Hang Lee; Gregory Sawicki; Ahmet Uluer; Leonard Sicilian; Isabel Neuringer; Catherine M Gordon; Mary L Bouxsein; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.